Another Low Blow For Raising HDL; Merck’s Tredaptive Fails Phase III Trial
This article was originally published in Pharmaceutical Approvals Monthly
With Tredaptive’s failure to meet the primary endpoint in the HPS2-THRIVE study, Merck announces it does not plan to seek regulatory approval of the niacin/laropiprant combination pill in the U.S.
You may also be interested in...
When Phase III clinical trial failures happen it is a painful blow – to the drug manufacturer, to investors and to patients. Scrip takes a look at some of the biggest Phase III surprises since 2010.
Merck’s recent sale of its consume health business to Bayer involved a side bet on a new class of antihypertensive, which could mark a return to cardiovascular for Merck.
A brief mention in an SEC filing revealed that Merck has ceased the development of a combination cholesterol pill; the once hot ‘0524 program had languished in late-stages for several years.